PuSH - Publikationsserver des Helmholtz Zentrums München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Sánchez-Garrido, M.A. ; Brandt, S. ; Clemmensen, C. ; Müller, T.D. ; DiMarchi, R.D.* ; Tschöp, M.H.

GLP-1/glucagon receptor co-agonism for treatment of obesity.

Diabetologia 60, 1851–1861 (2017)
Verlagsversion DOI PMC
Open Access Hybrid
Over a relatively short period, obesity and type 2 diabetes have come to represent a large medical and economic burden to global societies. The epidemic rise in the prevalence of obesity has metabolic consequences and is paralleled by an increased occurrence of other diseases, such as diabetes, cancer and cardiovascular complications. Together, obesity and type 2 diabetes constitute one of the more preventable causes of premature death and the identification of novel, safe and effective anti-obesity drugs is of utmost importance. Pharmacological attempts to treat obesity have had limited success, with notable adverse effects, rendering bariatric surgery as the only current therapy for substantially improving body weight. Novel unimolecular, multifunctional peptides have emerged as one of the most promising medicinal approaches to enhance metabolic efficacy and restore normal body weight. In this review, we will mainly focus on the discovery and translational relevance of dual agonists that pharmacologically function at the receptors for glucagon and glucagon-like peptide-1. Such peptides have advanced to clinical evaluation and inspired the pursuit of multiple related approaches to achieving polypharmacy within single molecules.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Scopus
Cited By
Altmetric
6.080
1.732
83
106
Tags
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Journalartikel
Dokumenttyp Review
Schlagwörter Co-agonism ; Dual Agonism ; Glp-1 ; Glucagon ; Multi-agonist ; Obesity ; Pharmacology ; Review ; Translational ; Type 2 Diabetes; Glucagon-like Peptide-1; Type-2 Diabetes-mellitus; Human Glp-1 Analog; Beta-cell Failure; Weight-loss; Double-blind; Food-intake; Antagonist Ly2409021; Nonhuman-primates; Bariatric Surgery
Sprache englisch
Veröffentlichungsjahr 2017
HGF-Berichtsjahr 2017
ISSN (print) / ISBN 0012-186X
e-ISSN 1432-0428
Zeitschrift Diabetologia
Quellenangaben Band: 60, Heft: 10, Seiten: 1851–1861 Artikelnummer: , Supplement: ,
Verlag Springer
Verlagsort Berlin ; Heidelberg [u.a.]
Begutachtungsstatus Peer reviewed
Institut(e) Institute of Diabetes and Obesity (IDO)
POF Topic(s) 30201 - Metabolic Health
90000 - German Center for Diabetes Research
Forschungsfeld(er) Helmholtz Diabetes Center
PSP-Element(e) G-502200-001
G-502200-006
G-501900-221
DOI 10.1007/s00125-017-4354-8
WOS ID WOS:000408770300002
Scopus ID 85025443695
PubMed ID 28733905
Erfassungsdatum 2017-08-03
[➜Korrektur melden]